The present invention provides a mutant chicken interleukin-1β protein as a chicken interleukin-1β antagonist, which has a substituted peptide at position 117 and/or 118 of wild-type chicken interleukin-1β peptides. The mutant chicken interleukin-1β protein is created by using point mutation in a method genetic engineering; it can significantly inhibit proliferation of avian virus, such as avian influenza virus, avian reovirus and Marek's disease virus, and avian inflammation response. Therefore, the mutant chicken interleukin-1β protein of the present invention can be used as antiviral and anti-inflammatory medication.

The present invention provides a mutant chicken interleukin-1β protein as a chicken interleukin-1β antagonist, which has a substituted peptide at position 117 and/or 118 of wild-type chicken interleukin-1β peptides. The mutant chicken interleukin-1β protein is created by using point mutation in a method genetic engineering; it can significantly inhibit proliferation of avian virus, such as avian influenza virus, avian reovirus and Marek's disease virus, and avian inflammation response. Therefore, the mutant chicken interleukin-1β protein of the present invention can be used as antiviral and anti-inflammatory medication.

The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.

The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.

Provided herein are immunoresponsive cells having IL-1 superfamily activities with spatiotemporal restriction. The immunoresponsive cells can further express a protease for regulating the IL-1 superfamily activities, and a chimeric antigen receptor (CAR) or a parallel CAR. Also provided herein are methods of preparing the immunoresponsive cells and methods of directing T cell mediated immune response using the immunoresponsive cells.

Provided herein are immunoresponsive cells having IL-1 superfamily activities with spatiotemporal restriction. The immunoresponsive cells can further express a protease for regulating the IL-1 superfamily activities, and a chimeric antigen receptor (CAR) or a parallel CAR. Also provided herein are methods of preparing the immunoresponsive cells and methods of directing T cell mediated immune response using the immunoresponsive cells.

The present invention relates, in part, to agents that bind PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-L1 targeting moiety and their use in the treatment of various diseases.

The present invention relates, in part, to agents that bind PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-L1 targeting moiety and their use in the treatment of various diseases.

Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and/or treating cancer or infectious disease.

Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and/or treating cancer or infectious disease.